eGFR Interpretation and Medication Dosing
Primary Recommendation
Prescribers must adjust medication doses based on eGFR, using the indexed value (mL/min/1.73 m²) reported by laboratories for initial assessment, but converting to absolute (de-indexed) GFR when dosing drugs with narrow therapeutic windows or in patients with extreme body size. 1
Understanding eGFR Values
Initial Assessment
- Use creatinine-based eGFR (eGFRcr) as the initial test for kidney function assessment, as it is routinely available on basic metabolic panels 1
- eGFR values are reported as indexed to body surface area (mL/min/1.73 m²), which standardizes results across different body sizes 1
- Normal eGFR ranges from 90-125 mL/min/1.73 m² in healthy adults, declining progressively with age (median 104-106 at age 40, declining to 45-50 at age 100) 2
CKD Staging Based on eGFR
- Stage G1: ≥90 mL/min/1.73 m² (normal or high, with other kidney damage markers) 1
- Stage G2: 60-89 mL/min/1.73 m² (mildly decreased) 1
- Stage G3a: 45-59 mL/min/1.73 m² (mildly to moderately decreased) 1
- Stage G3b: 30-44 mL/min/1.73 m² (moderately to severely decreased) 1
- Stage G4: 15-29 mL/min/1.73 m² (severely decreased) 1
- Stage G5: <15 mL/min/1.73 m² (kidney failure) 1
When to Question eGFR Accuracy
Consider measuring cystatin C and using eGFRcr-cys when:
- Extremes of muscle mass (bodybuilders, amputees, severe malnutrition, sarcopenia) 1
- Extremes of body size (BMI <18.5 or >35 kg/m²) 3, 4
- Vegetarian diet or creatine supplementation 1
- Precision required for drugs with narrow therapeutic indices 1
Consider direct GFR measurement when:
- eGFRcr-cys remains unreliable (high inflammation, high catabolic states, exogenous steroid use) 1
- Critical treatment decisions depend on precise GFR (chemotherapy dosing, living kidney donation evaluation) 1
Medication Dosing Principles
General Approach
All prescribers must take GFR into account when dosing renally cleared or nephrotoxic medications (Grade 1A recommendation). 1
De-indexing for Drug Dosing
For patients with body surface area significantly different from 1.73 m²:
- Calculate absolute GFR = eGFR × (patient BSA / 1.73) 5
- Use de-indexed GFR for drugs with narrow therapeutic windows (digoxin, lithium, aminoglycosides, chemotherapy agents) 1
- This prevents underdosing in larger patients and overdosing in smaller patients 3, 6
- Approximately 90% of patients have BSA >1.73 m², meaning indexed eGFR underestimates their true clearance 3
Specific Medication Adjustments by eGFR
Diabetes Medications
Metformin:
- Continue at full dose if eGFR ≥45 mL/min/1.73 m² 1
- Review use and reduce to 1000 mg daily if eGFR 30-44 mL/min/1.73 m² 1
- Discontinue if eGFR <30 mL/min/1.73 m² 1
- Temporarily hold during acute illness, dehydration, surgery, or contrast administration 1
SGLT2 Inhibitors:
- Initiate if eGFR ≥20 mL/min/1.73 m² for agents with proven kidney/cardiovascular benefit 1
- Once started, continue even as eGFR declines below initiation threshold 1
- Canagliflozin: avoid initiating if eGFR <60, discontinue if persistently <45 1
- Dapagliflozin: avoid initiating if eGFR <60, contraindicated if <30 1
- Empagliflozin: no adjustment if ≥45, discontinue if persistently <45 1
DPP-4 Inhibitors:
- Sitagliptin: 100 mg daily if eGFR >50; 25 mg daily if eGFR <30 1
- Saxagliptin: no adjustment if eGFR ≥45; 2.5 mg daily if eGFR ≤45 1
- Linagliptin: no adjustment required (hepatically cleared) 1
- Alogliptin: 25 mg if eGFR >60; 12.5 mg if 30-60; 6.25 mg if <30 1
GLP-1 Receptor Agonists:
- Exenatide: caution if eGFR 30-50, contraindicated if <30 1
- Lixisenatide: monitor closely if eGFR 15-59, avoid if <15 1
- Long-acting agents (dulaglutide, semaglutide): recommended for cardiovascular benefit in CKD 1
Sulfonylureas:
- Glipizide: conservative initial dose (2.5 mg) if eGFR <50, use caution with long-acting formulations 1
- Glimepiride: start 1 mg daily, consider alternative if eGFR <15 1
- Glyburide: avoid use entirely (renally cleared, high hypoglycemia risk) 1
Insulin:
- Reduce basal insulin by 25-30% in CKD stage 3 (eGFR 30-59) 1
- Reduce total daily dose by 35-50% in CKD stage 5 (eGFR <15) 1
- Reduce basal insulin by 25% on pre-hemodialysis days 1
Cardiovascular Medications
ACE Inhibitors and ARBs:
- Continue in all CKD stages for patients with hypertension and albuminuria 1
- Titrate to maximum tolerated dose for nephroprotection 1
- Check potassium and eGFR within 1 week of initiation or dose change 1
- Hold if potassium >5.5 mmol/L or eGFR declines >30% from baseline 7
- Temporarily discontinue during acute illness, dehydration, or contrast exposure 1
- Do not routinely discontinue when eGFR falls below 30 mL/min/1.73 m²—nephroprotection persists 7
Digoxin:
- Requires dose reduction based on plasma concentrations due to reduced renal clearance 5
- Temporarily discontinue during acute illness in patients with eGFR <60 1
Statins:
- Recommended for all patients with diabetes and CKD (moderate intensity for primary prevention, high intensity for known ASCVD) 1
- No dose adjustment required based on eGFR alone 1
Antibiotics
Aminoglycosides:
- Require dose reduction and/or extended intervals when eGFR <60 5
- Mandatory monitoring of trough and peak levels 5
Fluoroquinolones:
- Dose reduction by 50% when eGFR <45 5
Tetracyclines:
- Dose reduction when eGFR <45, can exacerbate uremia 5
Beta-lactams (e.g., Augmentin):
- Dose adjustment required at eGFR ≤30 8
- Monitor renal function 2-3 days after initiation, then weekly 8
- Hold during acute illness or dehydration 8
Other High-Risk Medications
NSAIDs:
- Avoid entirely when eGFR <30 5
- Prolonged therapy not recommended when eGFR <60 5
- Temporarily discontinue during acute illness in all CKD patients 1
Lithium:
- Requires regular monitoring of GFR, electrolytes, and drug levels 1
- Temporarily discontinue during acute illness 1
Opioids:
- Dose reduction required when eGFR <60 due to accumulation of active metabolites 5
Low-Molecular-Weight Heparins:
- Dose reduction when eGFR <30, standard dosing acceptable at eGFR 50 with monitoring 5
Monitoring Protocol
Baseline Assessment
- Measure serum creatinine and calculate eGFR 1
- Obtain spot urine albumin-to-creatinine ratio (ACR) 1
- Confirm persistence of abnormalities over ≥3 months before diagnosing CKD 1
Ongoing Monitoring
For patients on renally cleared or nephrotoxic drugs:
- Check eGFR and potassium within 1 week of starting or changing dose of RAAS inhibitors 1, 7
- Monthly monitoring for first 3 months, then quarterly if stable 7
- More frequent monitoring for drugs with narrow therapeutic indices (aminoglycosides, digoxin, lithium) 1, 5
Annual CKD screening:
Critical "Sick Day Rules"
Temporarily discontinue the following medications during acute illness, dehydration, diarrhea, vomiting, surgery, or contrast administration in patients with eGFR <60:
- RAAS blockers (ACE inhibitors, ARBs, aldosterone antagonists, direct renin inhibitors) 1, 7
- Diuretics 1
- NSAIDs 1
- Metformin 1
- Lithium 1
- Digoxin 1
Resume only after renal function stabilizes and patient is adequately hydrated. 7, 8
Common Pitfalls to Avoid
Calculation Errors
- Do not use indexed eGFR for drug dosing in patients with extreme body size (BMI <18.5 or >35)—convert to absolute GFR 3, 4, 6
- Do not rely on serum creatinine alone in elderly or sarcopenic patients—it underestimates kidney dysfunction 9
- Do not assume eGFR equations are accurate in extremes of muscle mass—consider cystatin C or measured GFR 1, 4
Medication Management
- Do not automatically discontinue ACE inhibitors or ARBs when eGFR falls below 30—nephroprotection continues 7
- Do not continue glyburide in any stage of CKD—high hypoglycemia risk 1
- Do not combine ACE inhibitors with ARBs in CKD—markedly increases hyperkalemia risk 7
- Do not prescribe NSAIDs chronically in patients with eGFR <60—increases AKI risk 5, 8
Monitoring Failures
- Do not forget to check potassium within 1 week of starting RAAS inhibitors 7
- Do not ignore an acute eGFR decline >30%—hold RAAS inhibitors and investigate 7
- Do not continue nephrotoxic drugs during acute illness without reassessing renal function 8